Applied Genetic Technologies Corporation (AGTC) Buy Target $4.26 – Sell Target $6.90

Trade Setup

Buy Target $4.26Sell Target 1 $5.50
Trailing Stop 20%Sell Target 2 $6.90

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.